Women Turn to Off-Label Testosterone for Libido as FDA Re-evaluates Approval
Women seeking treatment for low libido are increasingly turning to testosterone, despite the U.S. Food and Drug Administration having yet to approve any female-specific product for this use.
Interest in the hormone is rising across the United States, with prescription rates for all female uses climbing from 0.4 per 1,000 women in 2018 to 1.8 per 1,000 women in 2026, according to recent data.
Key Clinical Takeaways:
- Testosterone is not currently FDA-approved for female libido, though it is used off-label by some practitioners.
- Clinical trials face challenges with high placebo response rates, complicating the path to regulatory approval.
- Long-term safety data on cardiovascular health and breast cancer risk are still being studied.
Jessica Yih, a urologist at the University of California, Irvine Health, reports that inquiries about testosterone for sexual dysfunction are coming from all directions. While the hormone is approved for female use in countries including the United Kingdom and Australia, American women often must rely on off-label prescriptions.
Yih, who coauthored a 2026 research review in The Journal of Sexual Medicine, observed that testosterone may increase the brain’s receptivity to sexual stimuli while enhancing blood flow to the genitals.
The path to domestic approval has been historically difficult. In 2004, an FDA advisory panel unanimously rejected a testosterone patch for women, citing insufficient safety data. By 2011, two separate Phase III trials failed to show that testosterone therapy worked better than a placebo, a standard requirement for FDA drug approval.
“The treatment was a victim of its own success,” said Tami Rowen, an ob-gyn at UC San Francisco, noting that high patient expectations likely influenced the results in the placebo groups.
Regulators are currently re-evaluating the role of the hormone in women’s health. In September, the FDA held a public meeting to discuss testosterone use in menopausal women, aiming to guide future research and potential development. Kaveeta Vasisht, the FDA’s associate commissioner for women’s health, stated the meeting was held with the goal of informing future research and potential drug development in this area.
Researchers are also examining alternative, non-hormonal options for those experiencing low sexual desire. The FDA previously approved Addyi in 2015 for premenopausal women and Vyleesi in 2019. Last year, regulators expanded the indication for Addyi to include postmenopausal women younger than 65. Meanwhile, new candidates such as Lybrido are entering the pipeline, with a Phase III clinical trial planned in Europe to test its efficacy in enhancing both mental drive and physical arousal.
Despite the growing demand, clinicians emphasize that significant knowledge gaps persist regarding the long-term biological impact of testosterone therapy. Yih said that researchers still need to determine how, if at all, sustained use affects the risk of breast cancer and heart disease.
While psychological therapies and FDA-approved non-hormonal medications remain the current standard of care, the appetite for new, effective options remains high. “Women deserve better than placebo,” said Rowen.
Beyond her current clinical practice, Jessica Yih completed her medical degree at the Wayne State University School of Medicine in 2012. Following her graduation, she underwent six years of residency training in urology at Case Western Reserve University and University Hospitals Cleveland Medical Center, concluding in 2019.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.